HHS Bypasses FDA Approval for Six Peptides via Enforcement Discretion

Key points

• HHS will not pursue legal action against compounding pharmacies making BPC-157, epitalon, KPV, MOTS-c, semax, and TB-500.
• The policy applies only to small 503A compounding facilities, not larger outsourcing facilities, potentially limiting supply.
• Compounding pharmacies must now certify compound identity and purity and report side effects, a new requirement.
• The FDA’s own scientists previously concluded there is insufficient data to prove these peptides are safe or effective.
• The move follows a July advisory panel vote that included members with ties to the peptide industry.

Background

This development follows a series of regulatory shifts in 2026. In October, the White House proposed deregulating unapproved peptides despite safety warnings, aligning with the Make America Healthy (MAHA) agenda. Earlier that month, an FDA advisory panel voted to ease restrictions, though FDA scientists recommended against it due to a lack of evidence. Reports of adverse effects, including neurological issues and organ damage, have grown among users of gray-market peptides, prompting concerns about the risks of bypassing rigorous clinical trials.

How outlets are covering it

Proponents, including the Alliance for Pharmacy Compounding and HHS, argue that allowing compounding provides a safer, more accountable alternative to the unregulated gray market, where products are often sourced from sketchy overseas suppliers. They emphasize that new requirements for purity certification and side-effect reporting enhance oversight. Conversely, critics such as Public Citizen and the Partnership for Safe Medicines condemn the move as a sabotage of FDA standards. They argue that Kennedy acted unilaterally, bypassing the standard rulemaking process, and that the FDA’s own scientists had recommended against the change. Critics warn that the policy exposes Americans to untested substances and undermines public health protections.

Why it matters

This policy shift represents a significant departure from traditional FDA regulatory practices, potentially setting a precedent for bypassing safety reviews for other unapproved drugs. It directly impacts consumer access to wellness products popular among younger demographics and raises questions about the balance between patient access and regulatory safety in the US healthcare system.

What to watch

The formal rulemaking process to add these peptides to the FDA’s bulk drugs substances list is expected to take several months. In the interim, small compounding pharmacies may struggle to meet demand due to limited capacity and the need to verify ingredient purity. Consumer advocacy groups may continue to petition the FDA to reverse the enforcement discretion, while the public may face a gap between demand and supply for these compounds.